Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC), a diversified biopharmaceutical company, is focused on discovering, developing, and commercializing innovative mechanism-targeted drugs to treat human cancers and other serious disorders. The company’s strategic goal is to discover and develop oral anticancer agents that target the cell cycle with the intent to slow the growth of tumors or even shrink their size while enhancing the patient’s quality of life. For further information, visit the Company’s web site at www.cyclacel.com.
- 17 years ago
QualityStocks
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Onar Holding Corporation (OTCQB: ONAR) Details Board Additions, AI Partnerships and M&A Moves
Onar (OTCQB: ONAR), a marketing technology company and global network of performance-driven agencies, issued a…
-
QualityStocksNewsBreaks – Vision Marine Technologies Inc. (NASDAQ: VMAR) Sees 504% Boat Sales Surge, Slashes Debt Following Nautical Ventures Acquisition
Vision Marine Technologies (NASDAQ: VMAR), a leader in electric marine propulsion and multi-brand boat…
-
Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Secures $18.4M DoD Award to Fast-Track Heavy Rare Earth Independence
This phase 2 award builds on phase 1 success, during which Ucore successfully separated two heavy…